196TiP A phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies. (December 2022) - Lakhani, N.; Hamid, O.; Braña, I.; Reguera Puertas, P.; Lopez Criado, M.P.; Swiecicki, P.L.; De Miguel Luken, M.J.; Gil Martín, M.; Khong, H.; Moreno Garcia, V.; Lostes Bardaji, M.J.; Sun, F.; et al.